Osteopore Ltd. (AU:OSX) has released an update.
Osteopore Ltd., a leader in 3D-printed bioresorbable implants, has announced a collaboration with RxCell Inc., a U.S. biotech company specializing in induced pluripotent stem cell (iPSC) technology. This partnership marks Osteopore’s expansion into the burgeoning scaffold-based cell therapy market, promising to advance regenerative medicine and improve patient recovery outcomes. The deal includes the formation of a Technology Advisory Committee to explore co-development and resource sharing, with the potential for seeking third-party funding.
For further insights into AU:OSX stock, check out TipRanks’ Stock Analysis page.